Teva Pharma (TEVA): Cutting PT "Well Below" Consensus - RBC

November 14, 2016 7:13 AM EST
Get Alerts TEVA Hot Sheet
Price: $35.27 --0%

Rating Summary:
    21 Buy, 18 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade TEVA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Teva Pharma (NYSE: TEVA) but cut his price target to $58 from $71. TEVA will provide 3Q results and a guidance update on Tuesday and the analyst is lowering forecasts well below consensus ahead of another potential reset.

The stock is down 25% since 7/13 (post-AGN) guidance and notably down 20% since 9/9 "generics day" update suggesting that another cut is anticipated.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $40.65 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

RBC Capital

Add Your Comment